HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients
- 3 June 2018
- journal article
- letter
- Published by Elsevier in Annals of Oncology
- Vol. 29 (7) , 1598-1599
Abstract
Brain metastases from colorectal cancer (CRC) are a rare but increasing event as patients survive longer. While HER2 gene amplification in breast cancer is well described and known to increase risk of brain metastases [1], information in CRC patients with brain metastases is lacking. A multi-centre phase II trial has shown that HER2-directed therapies are efficacious in HER2 positive (HER2+) stage IV CRC without brain metastases [2]. If HER2 is enriched in CRC patients with brain metastases, it may provide a possible therapeutic target.Keywords
Funding Information
- National Cancer Centre Singapore Research Fund
This publication has 3 references indexed in Scilit:
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2016
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyLaboratory Investigation, 2015
- Metastatic breast cancer subtypes and central nervous system metastasesThe Breast, 2014